Kaleido Biosciences CEO Daniel Menichella receives $3.9M in 2020
Kaleido Biosciences reports 2020 executive compensation
By ExecPay News
Published: May 5, 2021
Kaleido Biosciences reported fiscal year 2020 executive compensation information on May 5, 2021.
In 2020, four executives at Kaleido Biosciences received on average a compensation package of $1.9M, a 15% increase compared to previous year.
Average pay of disclosed executives at Kaleido Biosciences
Daniel Menichella, Chief Executive Officer, received $3.9M in total. 96% of Menichella's compensation, or $3.8M, was in option awards. Menichella also received $49K in non-equity incentive plan, $119K in salary, as well as $1.7K in other compensation.
Katharine Knobil, Chief Marketing Officer, received a compensation package of $1.5M, which increased by 20% compared to previous year. 54% of the compensation package, or $806K, was in option awards.
William Duke, Jr, Chief Financial Officer, earned $1.2M in 2020, a 30% decrease compared to previous year.
Alison Lawton, Chief Executive Officer, received $1.1M in 2020, which decreases by 61% compared to 2019.
Related executives
You may also like
Source: SEC filing on May 5, 2021.